Stock Events

Stock Events

Acticor Biotech 

€0.25
14
-€0.01-1.96% Monday 14:36

Statistics

Day High
0.25
Day Low
0.25
52W High
4.66
52W Low
0.22
Volume
13,801
Avg. Volume
230
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26FebExpected
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Q2 2024
Q3 2024
Q4 2024
-0.45
-0.3
-0.15
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-18.64MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALACT.PA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a leading biopharmaceutical company that competes with Acticor Biotech in the development of treatments for cardiovascular diseases, including thrombosis, which is a focus area for Acticor Biotech.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical corporation with a broad portfolio that includes drugs for cardiovascular diseases, directly competing with Acticor Biotech's thrombosis and related cardiovascular treatments.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is involved in the development of treatments for blood and endocrine disorders, including conditions related to thrombosis and cardiovascular diseases, making it a competitor to Acticor Biotech.
Sanofi
SNY
Mkt Cap124.45B
Sanofi operates globally in the pharmaceutical sector, with a focus on cardiovascular diseases among others, competing with Acticor Biotech in the area of thrombosis treatment.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a strong emphasis on cardiovascular, renal, and metabolism medication, competing in the same therapeutic areas as Acticor Biotech.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, develops medications for various diseases, including cardiovascular conditions, making it a competitor to Acticor Biotech.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, with products targeting cardiovascular diseases among others, competing with Acticor Biotech in the development of innovative treatments.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is known for its wide range of pharmaceutical products, including those for cardiovascular health, directly competing with Acticor Biotech's focus on thrombosis and related conditions.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company is a global pharmaceutical company with a focus on several therapeutic areas, including cardiovascular diseases, competing with Acticor Biotech in research and development of treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of medicines for serious medical conditions, including cardiovascular diseases, competing with Acticor Biotech in innovation and market share.

About

Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Show more...
CEO
Dr. Gilles Avenard M.D.
Employees
31
Country
FR
ISIN
FR0014005OJ5

Listings

0 Comments

Share your thoughts

FAQ

What is Acticor Biotech stock price today?▼
The current price of ALACT.PA is €0.25 EUR — it has decreased by -1.96% in the past 24 hours. Watch Acticor Biotech stock price performance more closely on the chart.
What is Acticor Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acticor Biotech stocks are traded under the ticker ALACT.PA.
What is Acticor Biotech revenue for the last year?▼
Acticor Biotech revenue for the last year amounts to 0 EUR.
What is Acticor Biotech net income for the last year?▼
ALACT.PA net income for the last year is -18.64M EUR.
How many employees does Acticor Biotech have?▼
As of April 01, 2026, the company has 31 employees.
In which sector is Acticor Biotech located?▼
Acticor Biotech operates in the Communication Services sector.
When did Acticor Biotech complete a stock split?▼
Acticor Biotech has not had any recent stock splits.
Where is Acticor Biotech headquartered?▼
Acticor Biotech is headquartered in Paris, FR.